Cargando…

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond

Pirfenidone (PFD) slows the progression of idiopathic pulmonary fibrosis (IPF) by inhibiting the exaggerated fibrotic response and possibly through additional mechanisms, such as anti-inflammatory effects. PFD has also been evaluated in other fibrosing lung diseases. Myocardial fibrosis is a common...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aimo, Alberto, Spitaleri, Giosafat, Nieri, Dario, Tavanti, Laura Maria, Meschi, Claudia, Panichella, Giorgia, Lupón, Josep, Pistelli, Francesco, Carrozzi, Laura, Bayes-Genis, Antoni, Emdin, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Radcliffe Cardiology 2022
Materias:	Treatment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062707/ https://www.ncbi.nlm.nih.gov/pubmed/35516794 http://dx.doi.org/10.15420/cfr.2021.30

Ejemplares similares

Pirfenidone as a novel cardiac protective treatment
por: Aimo, Alberto, et al.
Publicado: (2021)

Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis
por: Aimo, Alberto, et al.
Publicado: (2022)

Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction
por: Castiglione, Vincenzo, et al.
Publicado: (2023)

Gender-Related Differences in Heart Failure Biomarkers
por: Cediel, Germán, et al.
Publicado: (2021)

Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
por: Aimo, Alberto, et al.
Publicado: (2022)

Advanced remote care for heart failure in times of COVID-19 using an implantable pulmonary artery pressure sensor: the new normal
por: Bayes-Genis, Antoni, et al.
Publicado: (2020)

The Potential Anti-remodeling Effect of Paroxetine After Myocardial Infarction May Be Blunted by Beta-Blockers
por: Iborra-Egea, Oriol, et al.
Publicado: (2022)

Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?
por: Lupón, Josep, et al.
Publicado: (2021)

Can Natriuretic Peptides be Used to Guide Therapy?
por: Bayes-Genis, Antoni, et al.
Publicado: (2016)

Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence
por: Bayes-Genis, Antoni, et al.
Publicado: (2021)

Atrial amyloidosis: mechanisms and clinical manifestations
por: Vergaro, Giuseppe, et al.
Publicado: (2022)

The influence of sex and body mass index on the association between soluble neprilysin and risk of heart failure hospitalizations
por: Núñez, Julio, et al.
Publicado: (2021)

Lung ultrasound in outpatients with heart failure: the wet‐to‐dry HF study
por: Domingo, Mar, et al.
Publicado: (2021)

Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis
por: Morfino, Paolo, et al.
Publicado: (2022)

Cause of Death in Heart Failure Based on Etiology: Long-Term Cohort Study of All-Cause and Cardiovascular Mortality
por: Spitaleri, Giosafat, et al.
Publicado: (2022)

Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy
por: Morfino, Paolo, et al.
Publicado: (2022)

Mortality trends in an ambulatory multidisciplinary heart failure unit from 2001 to 2018
por: Spitaleri, Giosafat, et al.
Publicado: (2021)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

Lung ultrasound and biomarkers in primary care: Partners for a better management of patients with heart failure?
por: Domingo, Mar, et al.
Publicado: (2020)

Different Effects on Protein Expression of CDR132L, an Antisense Inhibitor of miR-132, and Standard Therapies for Myocardial Infarction
por: Iborra-Egea, Oriol, et al.
Publicado: (2022)

Caval Valve Implantation (CAVI): An Emerging Therapy for Treating Severe Tricuspid Regurgitation
por: Abdul-Jawad Altisent, Omar, et al.
Publicado: (2021)

Mortality Risk Prediction Dynamics After Heart Failure Treatment Optimization: Repeat Risk Assessment Using Online Risk Calculators
por: Codina, Pau, et al.
Publicado: (2022)

Transitioning from Preclinical to Clinical Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach
por: Bayes-Genis, Antoni, et al.
Publicado: (2020)

The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism
por: Sanguinetti, Chiara, et al.
Publicado: (2022)

Prognostic value of reverse remodelling criteria in heart failure with reduced or mid‐range ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

Real life data on nintedanib safety: idiopathic pulmonary fibrosis versus systemic sclerosis-interstitial lung disease and strategies adopted to manage adverse effects
por: Di Battista, Marco, et al.
Publicado: (2023)

Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension
por: Codina, Pau, et al.
Publicado: (2022)

Pirfenidone treatment of idiopathic pulmonary fibrosis
por: Gan, Ye, et al.
Publicado: (2011)

Potential role for clinical calibration to increase engagement with and application of home telemonitoring: a report from the HeartCycle programme
por: Gastelurrutia, Paloma, et al.
Publicado: (2016)

Efficacy of As-Needed Nalmefene in Alcohol-Dependent Patients with at Least a High Drinking Risk Level: Results from a Subgroup Analysis of Two Randomized Controlled 6-Month Studies
por: van den Brink, Wim, et al.
Publicado: (2013)

Development of a Novel Heart Failure Risk Tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN Bio-HF Calculator)
por: Lupón, Josep, et al.
Publicado: (2014)

Limited Value of Cystatin-C over Estimated Glomerular Filtration Rate for Heart Failure Risk Stratification
por: Zamora, Elisabet, et al.
Publicado: (2012)

The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent
Publicado: (2013)

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
por: Takeda, Yoshito, et al.
Publicado: (2014)

Reversibility in male idiopathic osteoporosis possible
por: Jamall, Ijaz S, et al.
Publicado: (2023)

The Future of Telemedicine in the Management of Heart Failure Patients
por: Silva-Cardoso, José, et al.
Publicado: (2021)

Impact of a ‘stent for life’ initiative on post‐ST elevation myocardial infarction heart failure: a 15 year heart failure clinic experience
por: Bayes‐Genis, Antoni, et al.
Publicado: (2017)

Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study
por: Revuelta‐López, Elena, et al.
Publicado: (2020)

Determination of HLA‐A, ‐B, ‐C, ‐DRB1 and ‐DQB1 allele and haplotype frequencies in heart failure patients
por: Roura, Santiago, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mr1hsbci980r7iti03grk9iihf